The potential to modulate GSDM proteins offers a hopeful avenue for the development of treatment strategies aimed at alleviating the burden of IIM by interrupting the pyroptosis cascade reaction. This evidence concerns the gene GSDMA and acquired idiopathic inflammatory myopathy.